Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients With Mild to Moderate Pemphigus (Vulgaris and Foliaceus)

Next Previous
X
Search
Trial Profile

An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients With Mild to Moderate Pemphigus (Vulgaris and Foliaceus)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efgartigimod alfa (Primary)
  • Indications Pemphigus; Pemphigus vulgaris
  • Focus Adverse reactions; Proof of concept
  • Sponsors argenx

    • Most Recent Events

    • 27 Apr 2023 Results of pooled analysis (phase 2 myasthenia gravis, phase 2 open-label in pemphigus, ADAPT, ADVANCE, and ADAPT+) assessing the safety profile of efgartigimod across different IgG-mediated disorders, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 01 Dec 2022 Results published in the Autoimmunity
    • 19 May 2022 Results presented in an argenx media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top